Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiko Nakashima

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Pharmaceutical Research|October 16, 2007
Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cellsChie Hirayama, Hiroshi Watanabe, Reiko Nakashima, et al.
International Journal of Hematology|April 28, 2009
Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemiaTatsuya Kawaguchi, Akinobu Hamada, Chie Hirayama, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Production of rAAV by plasmid transfection induces antiviral and inflammatory responses in suspension HEK293 cellsCheng-Han Chung, Christopher M Murphy, Vincent P Wingate, et al.
Diabetology International|September 27, 2021
Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trialFumio Sawano, Nozomu Kamei, Mitsue Miyahara, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Pharmaceutical Research|October 16, 2007
Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cellsChie Hirayama, Hiroshi Watanabe, Reiko Nakashima, et al.
International Journal of Hematology|April 28, 2009
Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemiaTatsuya Kawaguchi, Akinobu Hamada, Chie Hirayama, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Production of rAAV by plasmid transfection induces antiviral and inflammatory responses in suspension HEK293 cellsCheng-Han Chung, Christopher M Murphy, Vincent P Wingate, et al.
Diabetology International|September 27, 2021
Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trialFumio Sawano, Nozomu Kamei, Mitsue Miyahara, et al.
Pageof 2